Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168763 | 0.90 | HCRTR1 (0.46) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL166061 | 0.90 | HRH3 (0.51) | MEN1KMT2AHRH3KDM4EALDH1A1 | |
| SCHEMBL256458 | 0.81 | LRRK2 (0.62) | MET | |
| SCHEMBL257191 | 0.81 | LRRK2 (0.63) | — | |
| SCHEMBL167180 | 0.80 | PTGER1 (0.45) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL168090 | 0.79 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16098900 | 0.77 | MRGPRX4 (0.52) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16097621 | 0.74 | LMNA (0.52) | — | |
| SCHEMBL1763430 | 0.74 | MRGPRX4 (0.52) | — | |
| SCHEMBL166024 | 0.74 | SMN1; SMN2 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2611772-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | LRRK2, PARK7, BRSK2 | MEN1 4191/4885KMT2A 609/4885HRH3 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.